Metabolic and cardiovascular adverse events of systemic glucocorticoid therapy;Effets indésirables métaboliques et cardiovasculaires des corticothérapies systémiques

Revue de Medecine Interne

Volumn 34, Issue 5, 2013, Pages 303-309

  Fardet, L ^a  

^a CENTRE DE RECHERCHE SAINT ANTOINE   (France)

Author keywords

Cardiovascular events; Diabetes; Dyslipidemia; Glucocorticoids; High blood pressure; Lipodystrophy

Indexed keywords

GLUCOCORTICOID;

CARDIOVASCULAR DISEASE; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INCIDENCE; LIPODYSTROPHY; METABOLIC DISORDER; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PROPHYLAXIS; RISK FACTOR; SHORT SURVEY; SIDE EFFECT; WEIGHT GAIN;

DIABETES MELLITUS; DYSLIPIDEMIAS; GLUCOCORTICOIDS; HEART DISEASES; HUMANS; HYPERTENSION; LIPODYSTROPHY; METABOLIC DISEASES; RISK FACTORS; WEIGHT GAIN;

EID: 84876724998     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.12.005     Document Type: Short Survey

References (101)

1. Pivonello R., De Leo M., Vitale P., Cozzolino A., Simeoli C., De Martino M.C., et al. Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010, 92:77-81.
2. Schäcke H., Döcke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 2002, 96:23-43.
3. van Raalte D.H., Brands M., van der Zijl N.J., Muskiet M.H., Pouwels P.J.W., Ackermans M.T., et al. Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia 2011, 54:2103-2112.
4. Feldman-Billard S., Lissak B., Kassaei R., Benrabah R., Héron E. Short-term tolerance of pulse methylprednisolone therapy in patients with diabetes mellitus. Ophthalmology 2005, 112:511-515.
5. Blackburn D., Hux J., Mamdani M. Quantification of the risk of corticosteroid-induced diabetes mellitus among the elderly. J Gen Intern Med 2002, 17:717-720.
6. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994, 236:619-632.
7. Gurwitz J.H., Bohn R.L., Glynn R.J., Monane M., Mogun H., Avorn J. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med 1994, 154:97-101.
8. Gulliford M.C., Charlton J., Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 2006, 29:2728-2729.
9. Gabriel S.E., Sunku J., Salvarani C., O'Fallon W.M., Hunder G.G. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 1997, 40:1873-1878.
10. Boudreaux J.P., McHugh L., Canafax D.M., Ascher N., Sutherland D.E., Payne W., et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987, 44:376-381.
11. Depczynski B., Daly B., Campbell L.V., Chisholm D.J., Keogh A. Predicting the occurrence of diabetes mellitus in recipients of heart transplants. Diabet Med 2000, 17:15-19.
12. Friedman E.A., Shyh T.P., Beyer M.M., Manis T., Butt K.M. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985, 5:196-202.
13. Fisher J.E., Smith R.S., Lagrandeur R., Lorenz R.P. Gestational diabetes mellitus in women receiving beta-adrenergics and corticosteroids for threatened preterm delivery. Obstet Gynecol 1997, 90:880-883.
14. Raúl Ariza-Andraca C., Barile-Fabris L.A., Frati-Munari A.C., Baltazár-Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch Med Res 1998, 29:259-262.
15. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010, 123:1001-1006.
16. Andrade-Sierra J., Contreras A.M., Monteon F.J., Celis A., Gutierrez R., Montañez J.L., et al. Risk factors and incidence of posttransplant diabetes mellitus in Mexican kidney recipients. Arch Med Res 2006, 37:961-966.
17. Hjelmesaeth J., Hartmann A., Kofstad J., Stenstrøm J., Leivestad T., Egeland T., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997, 64:979-983.
18. Ha Y., Lee K.H., Jung S., Lee S.W., Lee S.K., Park Y.B. Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapy. Lupus 2011, 20:1027-1034.
19. Kim S.Y., Yoo C.G., Lee C.T., Chung H.S., Kim Y.W., Han S.K., et al. Incidence and risk factors of steroid-induced diabetes in patients with respiratory disease. J Korean Med Sci 2011, 26:264-267.
20. Uzu T., Harada T., Sakaguchi M., Kanasaki M., Isshiki K., Araki S., et al. Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 2007, 105:c54-c57.
21. Bruno A., Carucci P., Cassader M., Cavallo-Perin P., Gruden G., Olivetti C., et al. Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man. Eur J Clin Pharmacol 1994, 46:411-415.
22. Pagano G., Lombardi A., Ferraris G.M., Imbimbo B., Cavallo Perin P. Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol 1982, 22:469-471.
23. den Uyl D., van Raalte D.H., Nurmohamed M.T., Lems W.F., Bijlsma J.W.J., Hoes J.N., et al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012, 64:639-646.
24. Burt M.G., Roberts G.W., Aguilar-Loza N.R., Frith P., Stranks S.N. Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. J Clin Endocrinol Metab 2011, 96:1789-1796.
25. Burt M.G., Willenberg V.M., Petersons C.J., Smith M.D., Ahern M.J., Stranks S.N. Screening for diabetes in patients with inflammatory rheumatological disease administered long-term prednisolone: a cross-sectional study. Rheumatology (Oxford) 2012, 51:1112-1119.
26. Yuen K.C.J., McDaniel P.A., Riddle M.C. Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol (Oxf) 2012, 77:224-232.
27. Mazziotti G., Gazzaruso C., Giustina A. Diabetes in Cushing syndrome: basic and clinical aspects. Trends Endocrinol Metab 2011, 22:499-506.
28. Munir A., Newell-Price J. Management of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010, 92:82-85.
29. van Raalte D.H., van Genugten R.E., Linssen M.M.L., Ouwens D.M., Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 2011, 34:412-417.
30. Arner P., Gunnarsson R., Blomdahl S., Groth C.G. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983, 6:23-25.
31. Onwubalili J.K., Obineche E.N. High incidence of post-transplant diabetes mellitus in a single-centre study. Nephrol Dial Transplant 1992, 7:346-349.
32. Everson G.T., Trouillot T., Wachs M., Bak T., Steinberg T., Kam I., et al. Early steroid withdrawal in liver transplantation is safe and beneficial. Liver Transpl Surg 1999, 5:S48-S57.
33. Hricik D.E., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374-377.
34. Midtvedt K., Hjelmesaeth J., Hartmann A., Lund K., Paulsen D., Egeland T., et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 2004, 15:3233-3239.
35. Arnaldi G., Scandali V.M., Trementino L., Cardinaletti M., Appolloni G., Boscaro M. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology 2010, 92:86-90.
36. Christ-Crain M., Kola B., Lolli F., Fekete C., Seboek D., Wittmann G., et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008, 22:1672-1683.
37. el-Shaboury A.H., Hayes T.M. Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J 1973, 2:85-86.
38. Jefferys D.B., Lessof M.H., Mattock M.B. Corticosteroid treatment, serum lipids and coronary artery disease. Postgrad Med J 1980, 56:491-493.
39. Choi H.K., Seeger J.D. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005, 53:528-535.
40. Zimmerman J., Fainaru M., Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metab Clin Exp 1984, 33:521-526.
41. Brotman D.J., Girod J.P., Garcia M.J., Patel J.V., Gupta M., Posch A., et al. Effects of short-term glucocorticoids on cardiovascular biomarkers. J Clin Endocrinol Metab 2005, 90:3202-3208.
42. Ettinger W.H., Klinefelter H.F., Kwiterovitch P.O. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987, 63:167-172.
43. Kuroki Y., Kaji H., Kawano S., Kanda F., Takai Y., Kajikawa M., et al. Prospective short-term effects of glucocorticoid treatment on glucose and lipid metabolism in Japanese. Intern Med 2010, 49:897-902.
44. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88:5593-5602.
45. Greenman Y. Management of dyslipidemia in Cushing's syndrome. Neuroendocrinology 2010, 92:91-95.
46. Fardet L., Cabane J., Kettaneh A., Lebbé C., Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome. Rheumatology (Oxford) 2007, 46:1102-1106.
47. Pinheiro CH da J., Sousa Filho (de) W.M., Oliveira Neto (de) J., Marinho M de J.F., Motta Neto R., Smith M.M.R.L., et al. Exercise prevents cardiometabolic alterations induced by chronic use of glucocorticoids. Arq Bras Cardiol 2009, 93:400-408. [392-400].
48. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Généreau T., Tolédano C., et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007, 157:142-148.
49. Tataranni P.A., Larson D.E., Snitker S., Young J.B., Flatt J.P., Ravussin E. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol 1996, 271:E317-E325.
50. Chanson P., Salenave S. Metabolic syndrome in Cushing's syndrome. Neuroendocrinology 2010, 92:96-101.
51. Lee M.J., Gong D.W., Burkey B.F., Fried S.K. Pathways regulated by glucocorticoids in omental and subcutaneous human adipose tissues: a microarray study. Am J Physiol Endocrinol Metab 2011, 300:E571-E580.
52. Lundgren M., Burén J., Ruge T., Myrnäs T., Eriksson J.W. Glucocorticoids down-regulate glucose uptake capacity and insulin-signaling proteins in omental but not subcutaneous human adipocytes. J Clin Endocrinol Metab 2004, 89:2989-2997.
53. Fried S.K., Russell C.D., Grauso N.L., Brolin R.E. Lipoprotein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J Clin Invest 1993, 92:2191-2198.
54. Valassi E., Santos A., Yaneva M., Tóth M., Strasburger C.J., Chanson P., et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. Eur J Endocrinol 2011, 165:383-392.
55. Huscher D., Thiele K., Gromnica-Ihle E., Hein G., Demary W., Dreher R., et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis 2009, 68:1119-1124.
56. Horber F.F., Zürcher R.M., Herren H., Crivelli M.A., Robotti G., Frey F.J. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr 1986, 43:758-769.
57. Schou A.J., Heuck C., Wolthers O.D. Differential effects of short-term prednisolone treatment on peripheral and abdominal subcutaneous thickness in children assessed by ultrasound. Steroids 2003, 68:525-531.
58. Rockall A.G., Sohaib S.A., Evans D., Kaltsas G., Isidori A.M., Monson J.P., et al. Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome. Eur J Endocrinol 2003, 149:561-567.
59. Fardet L., Cabane J., Lebbé C., Morel P., Flahault A. Incidence and risk factors for corticosteroid-induced lipodystrophy: a prospective study. J Am Acad Dermatol 2007, 57:604-609.
60. Arena C., Morin A.S., Blanchon T., Hanslik T., Cabane J., Dupuy A., et al. Impact of glucocorticoid-induced adverse events on adherence in patients receiving long-term systemic glucocorticoid therapy. Br J Dermatol 2010, 163:832-837.
61. Fardet L., Petersen I., Nazareth I. Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study. BMJ 2012, 345:e4928.
62. Curtis J.R., Westfall A.O., Allison J., Bijlsma J.W., Freeman A., George V., et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006, 55:420-426.
63. Fardet L., Antuna-Puente B., Vatier C., Cervera P., Touati A., Simon T., et al. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clin Endocrinol 2012, [Internet].
64. Fardet L., Kettaneh A., Tiev K.P., Fabre B., Tolédano C., Cabane J., et al. Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy. Eur J Intern Med 2008, 19:340-344.
65. Barahona M.J., Sucunza N., Resmini E., Fernández-Real J.M., Ricart W., Moreno-Navarrete J.M., et al. Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome. J Clin Endocrinol Metab 2009, 94:3365-3371.
66. Fardet L., Flahault A., Kettaneh A., Tiev K.P., Tolédano C., Cabane J. Natural history of corticosteroid-induced lipodystrophy: a prospective follow-up of 37 patients. Rev Med Interne 2007, 28:825-831.
67. Geer E.B., Shen W., Strohmayer E., Post K.D., Freda P.U. Body composition and cardiovascular risk markers after remission of Cushing's disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 2012, 97:1702-1711.
68. Covar R.A., Leung D.Y., McCormick D., Steelman J., Zeitler P., Spahn J.D. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000, 106:651-659.
69. Panoulas V.F., Douglas K.M.J., Stavropoulos-Kalinoglou A., Metsios G.S., Nightingale P., Kita M.D., et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008, 47:72-75.
70. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest 1965, 48:287-290.
71. Truhan A.P., Ahmed A.R. Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. Ann Allergy 1989, 62:375-391.
72. Williamson P.M., Kelly J.J., Whitworth J.A. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens Suppl 1996, 14:S37-S41.
73. Whitworth J.A., Kelly J.J. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Endocrinol Invest 1995, 18:586-591.
74. Fardet L., Kettaneh A., Gérol J., Tolédano C., Tiev K.P., Cabane J. Short-term effect of dietary-sodium intake on arterial blood pressure of patients treated with systemic corticosteroids: a prospective, randomised, crossover study. Rev Med Interne 2009, 30:741-746.
75. Whitworth J.A., Schyvens C.G., Zhang Y., Mangos G.J., Kelly J.J. Glucocorticoid-induced hypertension: from mouse to man. Clin Exp Pharmacol Physiol 2001, 28:993-996.
76. Goodwin J.E., Zhang J., Geller D.S. A critical role for vascular smooth muscle in acute glucocorticoid-induced hypertension. J Am Soc Nephrol 2008, 19:1291-1299.
77. Mantero F., Boscaro M. Glucocorticoid-dependent hypertension. J Steroid Biochem Mol Biol 1992, 43:409-413.
78. Ong S.L.H., Whitworth J.A. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am 2011, 40:393-407.
79. Peppa M., Krania M., Raptis S.A. Hypertension and other morbidities with Cushing's syndrome associated with corticosteroids: a review. Integr Blood Press Control 2011, 4:7-16.
80. Sato A., Funder J.W., Okubo M., Kubota E., Saruta T. Glucocorticoid-induced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens 1995, 8:823-828.
81. Kamdem L.K., Hamilton L., Cheng C., Liu W., Yang W., Johnson J.A., et al. Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia. Pharmacogenet Genomics 2008, 18:507-514.
82. Whitworth J.A., Gordon D., Andrews J., Scoggins B.A. The hypertensive effect of synthetic glucocorticoids in man: role of sodium and volume. J Hypertens 1989, 7:537-549.
83. Fardet L., Hanslik T., Blanchon T., Perdoncini-Roux A., Kettaneh A., Tiev K.P., et al. Long-term systemic corticosteroid-therapy associated measures: description of the French internal medicine physicians' practices. Rev Med Interne 2008, 29:975-980.
84. Montrella-Waybill M., Clore J.N., Schoolwerth A.C., Watlington C.O. Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor. J Clin Endocrinol Metab 1991, 72:1060-1066.
85. Zacharieva S., Orbetzova M., Natchev E., Vergilova J., Andrewa M., Wipperrnann M., et al. Losartan in Cushing's syndrome. Methods Find Exp Clin Pharmacol 1998, 20:163-168.
86. Zacharieva S., Torbova S., Orbetzova M., Vergilova J., Nachev E., Wippermann M., et al. Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension. Methods Find Exp Clin Pharmacol 1998, 20:433-438.
87. Trementino L., Arnaldi G., Appolloni G., Daidone V., Scaroni C., Casonato A., et al. Coagulopathy in Cushing's syndrome. Neuroendocrinology 2010, 92:55-59.
88. Souverein P.C., Berard A., Van Staa T.P., Cooper C., Egberts A.C.G., Leufkens H.G.M., et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004, 90:859-865.
89. Varas-Lorenzo C., Rodriguez L.A.G., Maguire A., Castellsague J., Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis 2007, 192:376-383.
90. Wei L., MacDonald T.M., Walker B.R. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004, 141(10):764-770.
91. van der Hooft C.S., Heeringa J., Brusselle G.G., Hofman A., Witteman J.C.M., Kingma J.H., et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 2006, 166:1016-1020.
92. Clayton R.N., Raskauskiene D., Reulen R.C., Jones P.W. Mortality and morbidity in Cushing's disease over 50years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 2011, 96:632-642.
93. Pivonello R., Faggiano A., Lombardi G., Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am 2005, 34:327-339.
94. Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K.L., Furberg C.D., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52:1502-1517.
95. Cooper M.S., Stewart P.M. 11Beta-hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J Clin Endocrinol Metab 2009, 94:4645-4654.
96. Morton N.M. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease. Mol Cell Endocrinol 2010, 316:154-164.
97. Walker B.R., Andrew R. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease. Ann N Y Acad Sci 2006, 1083:165-184.
98. Iovino A., Paquot N., Scheen A.J. Reduction of obesity-related metabolic risk by modulating tissue exposition to cortisol. Rev Med Suisse 2010, 6:1608-1612.
99. Veilleux A., Laberge P.Y., Morency J., Noël S., Luu-The V., Tchernof A. Expression of genes related to glucocorticoid action in human subcutaneous and omental adipose tissue. J Steroid Biochem Mol Biol 2010, 122:28-34.
100. Anagnostis P., Athyros V.G., Tziomalos K., Karagiannis A., Mikhailidis D.P. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009, 94:2692-2701.
101. Andersson T., Simonyte K., Andrew R., Strand M., Burén J., Walker B.R., et al. Tissue-specific increases in 11beta-hydroxysteroid dehydrogenase type 1 in normal weight postmenopausal women. PLoS One 2009, 4:e8475.